Arjun Sahgal1, Michael W Chan1, Eshetu G Atenafu1, Laurence Masson-Cote1, Gaurav Bahl1, Eugene Yu1, Barbara-Ann Millar1, Caroline Chung1, Charles Catton1, Brian O'Sullivan1, Jonathan C Irish1, Ralph Gilbert1, Gelareh Zadeh1, Michael Cusimano1, Fred Gentili1, Normand J Laperriere1. 1. Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada (A.S.); Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada (A.S., L.M.-C., G.B., B.-A.M., C.C., C.C., B.O., N.J.L.); Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (M.W.C.); Department of Biostatistics, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada (E.G.A); Department of Radiology, University Health Network, University of Toronto, Toronto, Ontario, Canada (E.Y.); Department of Otolaryngology-Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada (J.C.I., R.G.); Division of Neurosurgery, Department of Surgery, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada (G.Z., F.G.); Department of Neurosurgery, St Michaels Hospital, University of Toronto, Toronto, Ontario, Canada (M.C.).
Abstract
BACKGROUND: We report our preliminary outcomes following high-dose image-guided intensity modulated radiotherapy (IG-IMRT) for skull base chordoma and chondrosarcoma. METHODS: Forty-two consecutive IG-IMRT patients, with either skull base chordoma (n = 24) or chondrosarcoma (n = 18) treated between August 2001 and December 2012 were reviewed. The median follow-up was 36 months (range, 3-90 mo) in the chordoma cohort, and 67 months (range, 15-125) in the chondrosarcoma cohort. Initial surgery included biopsy (7% of patients), subtotal resection (57% of patients), and gross total resection (36% of patients). The median IG-IMRT total doses in the chondrosarcoma and chordoma cohorts were 70 Gy and 76 Gy, respectively, delivered with 2 Gy/fraction. RESULTS: For the chordoma and chondrosarcoma cohorts, the 5-year overall survival and local control rates were 85.6% and 65.3%, and 87.8% and 88.1%, respectively. In total, 10 patients progressed locally: 8 were chordoma patients and 2 chondrosarcoma patients. Both chondrosarcoma failures were in higher-grade tumors (grades 2 and 3). None of the 8 patients with grade 1 chondrosarcoma failed, with a median follow-up of 77 months (range, 34-125). There were 8 radiation-induced late effects-the most significant was a radiation-induced secondary malignancy occurring 6.7 years following IG-IMRT. Gross total resection and age were predictors of local control in the chordoma and chondrosarcoma patients, respectively. CONCLUSIONS: We report favorable survival, local control and adverse event rates following high dose IG-IMRT. Further follow-up is needed to confirm long-term efficacy.
BACKGROUND: We report our preliminary outcomes following high-dose image-guided intensity modulated radiotherapy (IG-IMRT) for skull base chordoma and chondrosarcoma. METHODS: Forty-two consecutive IG-IMRT patients, with either skull base chordoma (n = 24) or chondrosarcoma (n = 18) treated between August 2001 and December 2012 were reviewed. The median follow-up was 36 months (range, 3-90 mo) in the chordoma cohort, and 67 months (range, 15-125) in the chondrosarcoma cohort. Initial surgery included biopsy (7% of patients), subtotal resection (57% of patients), and gross total resection (36% of patients). The median IG-IMRT total doses in the chondrosarcoma and chordoma cohorts were 70 Gy and 76 Gy, respectively, delivered with 2 Gy/fraction. RESULTS: For the chordoma and chondrosarcoma cohorts, the 5-year overall survival and local control rates were 85.6% and 65.3%, and 87.8% and 88.1%, respectively. In total, 10 patients progressed locally: 8 were chordomapatients and 2 chondrosarcomapatients. Both chondrosarcoma failures were in higher-grade tumors (grades 2 and 3). None of the 8 patients with grade 1 chondrosarcoma failed, with a median follow-up of 77 months (range, 34-125). There were 8 radiation-induced late effects-the most significant was a radiation-induced secondary malignancy occurring 6.7 years following IG-IMRT. Gross total resection and age were predictors of local control in the chordoma and chondrosarcomapatients, respectively. CONCLUSIONS: We report favorable survival, local control and adverse event rates following high dose IG-IMRT. Further follow-up is needed to confirm long-term efficacy.
Authors: M A Fagundes; E B Hug; N J Liebsch; W Daly; J Efird; J E Munzenrider Journal: Int J Radiat Oncol Biol Phys Date: 1995-10-15 Impact factor: 7.038
Authors: Matthias Uhl; Matthias Mattke; Thomas Welzel; Falk Roeder; Jan Oelmann; Gregor Habl; Alexandra Jensen; Malte Ellerbrock; Oliver Jäkel; Thomas Haberer; Klaus Herfarth; Jürgen Debus Journal: Cancer Date: 2014-06-19 Impact factor: 6.860
Authors: Juan J Martin; Ajay Niranjan; Douglas Kondziolka; John C Flickinger; Karl A Lozanne; L Dade Lunsford Journal: J Neurosurg Date: 2007-10 Impact factor: 5.115
Authors: Stella K Yoo; Ben A Strickland; Gabriel Zada; Shelly X Bian; Adam Garsa; Jason C Ye; Cheng Yu; Martin H Weiss; Bozena B Wrobel; Steven Giannotta; Eric L Chang Journal: J Neurol Surg B Skull Base Date: 2020-01-14
Authors: Edward W Jung; David L Jung; Ehsan H Balagamwala; Lilyana Angelov; John H Suh; Toufik Djemil; Anthony Magnelli; Samuel T Chao Journal: Technol Cancer Res Treat Date: 2016-06-03
Authors: Hirotaka Hasegawa; Kunal Vakharia; Christopher S Graffeo; Matthew L Carlson; Bruce E Pollock; Paul D Brown; Avital Perry; Jamie J Van Gompel; Colin L W Driscoll; Michael J Link Journal: J Neurooncol Date: 2021-04-27 Impact factor: 4.130
Authors: Adam L Holtzman; Ronny L Rotondo; Michael S Rutenberg; Daniel J Indelicato; Alexandra De Leo; Dinesh Rao; Jeet Patel; Christopher G Morris; William M Mendenhall Journal: Int J Part Ther Date: 2021-06-25